ArticleBMC research notes2026
Insulin resistance and serum adiponectin levels in Nigerian patients with type 2 diabetes mellitus: a case-control study.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study examined the association between adiponectin levels and markers of Insulin Resistance (IR) in obese and non-obese adults with type 2 diabetes. Insulin Resistance was estimated using HOMA-IR, while group differences were assessed using appropriate statistical tests. Multiple linear regression was applied to evaluate associations between adiponectin and obesity indices while adjusting for HOMA-IR.
resultsMean serum adiponectin did not differ significantly across obese diabetics, non-obese diabetics, and controls (5.9 ± 3.6 µg/mL, 6.4 ± 3.2 µg/mL, and 6.8 ± 3.5 µg/mL, respectively; p = 0.13). Mean HOMA-IR values were comparable among obese diabetics (1.4 ± 2.1), non-obese diabetics (1.3 ± 1.0), and controls (1.1 ± 0.6). In multivariable regression models, serum adiponectin was not independently associated with obesity indices or HOMA-IR (all p > 0.05). Serum adiponectin levels were not significantly different across the study groups, although numerically lower values were observed in obese individuals with diabetes. No significant relationship was found between adiponectin and clinical or biochemical markers of IR. These findings suggest that adiponectin may have limited utility as an isolated marker of IR in Nigerian adults with type 2 diabetes and underscore the need for larger, longitudinal studies to clarify its role.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.